The Use of Unlisted Billing Codes for Microsurgical Breast Reconstruction and Implications for Code Consolidation
Conclusion Coding practices for microsurgical breast reconstruction lacked uniformity in Massachusetts, and payments differed greatly between S2068 and CPT19364. Patients from more affluent towns were more likely to have S-code claims. Coding consolidation could impact access, as the majority of providers in Massachusetts might need to adapt their practices if the S-code were discontinued. [...] Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents | Abstract | Full text (Source: Journal of Reconstructive Microsurgery)
Source: Journal of Reconstructive Microsurgery - March 28, 2024 Category: Surgery Authors: Yang, Alan Z. Hyland, Colby J. Carty, Matthew J. Erdmann-Sager, Jessica Pusic, Andrea L. Broyles, Justin M. Tags: Original Article Source Type: research
Long-lasting, injectable HIV prevention drug set for “aggressive” roll-out in Africa
Tools to fight HIV tend to come late to sub-Saharan Africa, the region hardest hit by the epidemic. After powerful, lifesaving cocktails of HIV drugs came to market in 1996, it took 7 years before they began to reach large numbers of people living with the virus there. When pills to prevent, rather than treat, HIV infection were introduced in 2012—a strategy known as pre-exposure prophylaxis (PrEP)—Africa was again slow to benefit.
But with the next revolution in HIV prevention—an injectable, long-lasting version of PrEP—Africans may actually soon lead the pack. Not many people in rich countries have started ...
Source: Science of Aging Knowledge Environment - March 25, 2024 Category: Geriatrics Source Type: research
Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group
CONCLUSION: Insulin OOP caps were associated with reduced insulin OOP costs but no overall increases in insulin use. A proposed national insulin cap of $35 for commercially insured persons might lead to meaningful insulin OOP savings but have a limited effect on insulin use.PRIMARY FUNDING SOURCE: Centers for Disease Control and Prevention and National Institute of Diabetes and Digestive and Kidney Diseases.PMID:38527286 | DOI:10.7326/M23-1965 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 25, 2024 Category: Internal Medicine Authors: Laura F Garabedian Fang Zhang Rebecca Costa Stephanie Argetsinger Dennis Ross-Degnan J Frank Wharam Source Type: research
Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group
CONCLUSION: Insulin OOP caps were associated with reduced insulin OOP costs but no overall increases in insulin use. A proposed national insulin cap of $35 for commercially insured persons might lead to meaningful insulin OOP savings but have a limited effect on insulin use.PRIMARY FUNDING SOURCE: Centers for Disease Control and Prevention and National Institute of Diabetes and Digestive and Kidney Diseases.PMID:38527286 | DOI:10.7326/M23-1965 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 25, 2024 Category: Internal Medicine Authors: Laura F Garabedian Fang Zhang Rebecca Costa Stephanie Argetsinger Dennis Ross-Degnan J Frank Wharam Source Type: research
Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group
CONCLUSION: Insulin OOP caps were associated with reduced insulin OOP costs but no overall increases in insulin use. A proposed national insulin cap of $35 for commercially insured persons might lead to meaningful insulin OOP savings but have a limited effect on insulin use.PRIMARY FUNDING SOURCE: Centers for Disease Control and Prevention and National Institute of Diabetes and Digestive and Kidney Diseases.PMID:38527286 | DOI:10.7326/M23-1965 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 25, 2024 Category: Internal Medicine Authors: Laura F Garabedian Fang Zhang Rebecca Costa Stephanie Argetsinger Dennis Ross-Degnan J Frank Wharam Source Type: research
Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group
CONCLUSION: Insulin OOP caps were associated with reduced insulin OOP costs but no overall increases in insulin use. A proposed national insulin cap of $35 for commercially insured persons might lead to meaningful insulin OOP savings but have a limited effect on insulin use.PRIMARY FUNDING SOURCE: Centers for Disease Control and Prevention and National Institute of Diabetes and Digestive and Kidney Diseases.PMID:38527286 | DOI:10.7326/M23-1965 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 25, 2024 Category: Internal Medicine Authors: Laura F Garabedian Fang Zhang Rebecca Costa Stephanie Argetsinger Dennis Ross-Degnan J Frank Wharam Source Type: research
Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group
CONCLUSION: Insulin OOP caps were associated with reduced insulin OOP costs but no overall increases in insulin use. A proposed national insulin cap of $35 for commercially insured persons might lead to meaningful insulin OOP savings but have a limited effect on insulin use.PRIMARY FUNDING SOURCE: Centers for Disease Control and Prevention and National Institute of Diabetes and Digestive and Kidney Diseases.PMID:38527286 | DOI:10.7326/M23-1965 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 25, 2024 Category: Internal Medicine Authors: Laura F Garabedian Fang Zhang Rebecca Costa Stephanie Argetsinger Dennis Ross-Degnan J Frank Wharam Source Type: research
Why our genetic code should remain off-limits to life insurers
As DNA testing becomes routine, will life insurance companies start using our genetic code to inform their decisions, asks Jenny Kleeman (Source: New Scientist - Health)
Source: New Scientist - Health - March 20, 2024 Category: Consumer Health News Source Type: research
Impact of reimbursement systems on patient care – a systematic review of systematic reviews
ConclusionPatient care can be influenced by the choice of reimbursement system. The factors for successful implementation need to be further explored in future research. (Source: Health Economics Review)
Source: Health Economics Review - March 16, 2024 Category: International Medicine & Public Health Source Type: research
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
Summary of influences that led to introduction of frontal airbags on US passenger vehicles
CONCLUSION: In 1966, there was support from the US auto industry for a single source of safety regulations that apply to new vehicles sold in the US. This is evidenced by the unanimous passage by the House of Representatives and Senate of the Law that created the Federal auto safety regulatory framework. The Law also required seatbelts in new cars and prohibited States from making separate safety rules. However, the large safety benefits offered by seatbelts were negated because they were rarely used. Consequently, finding ways of providing high levels of protection without requiring action by occupants became a goal of th...
Source: Traffic Injury Prevention - March 13, 2024 Category: Accident Prevention Authors: Kennerly H Digges Source Type: research
Summary of influences that led to introduction of frontal airbags on US passenger vehicles
CONCLUSION: In 1966, there was support from the US auto industry for a single source of safety regulations that apply to new vehicles sold in the US. This is evidenced by the unanimous passage by the House of Representatives and Senate of the Law that created the Federal auto safety regulatory framework. The Law also required seatbelts in new cars and prohibited States from making separate safety rules. However, the large safety benefits offered by seatbelts were negated because they were rarely used. Consequently, finding ways of providing high levels of protection without requiring action by occupants became a goal of th...
Source: Traffic Injury Prevention - March 13, 2024 Category: Accident Prevention Authors: Kennerly H Digges Source Type: research
